People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

They both likely accomplish this by improving cardiovascular disease risk factors such as improving blood sugar control, improving blood pressure, promoting weight less, reducing inflammation, and ...

"These findings provide a clearer understanding of how glucagon functions in type 1 diabetes and offer a foundation for future research into therapeutic approaches. As researchers continue to explore ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on developing treatments for liver disease and obesity, has been garnering attention ...